Changes in list prices, net prices, and discounts for branded drugs in the US, 2007-2018
Importance Most studies that have examined drug prices have focused on list prices, without
accounting for manufacturer rebates and other discounts, which have substantially …
accounting for manufacturer rebates and other discounts, which have substantially …
Correlation between changes in brand-name drug prices and patient out-of-pocket costs
Importance List prices set by manufacturers for brand-name prescription drugs in the US
have been increasing faster than inflation, although confidential manufacturer rebates offset …
have been increasing faster than inflation, although confidential manufacturer rebates offset …
[HTML][HTML] Estimating rebates and other discounts received by Medicare Part D
WB Feldman, BN Rome, VC Raimond… - JAMA Health …, 2021 - jamanetwork.com
Importance Spending in Medicare Part D continues to increase. Yet, studies of Medicare
Part D are plagued by a common limitation: none can fully account for confidential rebates …
Part D are plagued by a common limitation: none can fully account for confidential rebates …
Prolonged increases in public-payer spending and prices after unapproved drug initiative approval of colchicine
N McCormick, ZS Wallace, C Yokose… - JAMA Internal …, 2021 - jamanetwork.com
Prolonged Increases in Public-Payer Spending and Prices After Unapproved Drug Initiative
Approval of Colchicine | Rheumatology | JAMA Internal Medicine | JAMA Network [Skip to …
Approval of Colchicine | Rheumatology | JAMA Internal Medicine | JAMA Network [Skip to …
Outpatient treatment at home for Medicare beneficiaries during and after the COVID-19 pandemic
On April 30, 2020, the Centers for Medicare & Medicaid Services (CMS) released an
unprecedented emergency policy waiver to increase capacity in response to coronavirus …
unprecedented emergency policy waiver to increase capacity in response to coronavirus …
Impact of novel systemic therapies on the first‐year costs of care for melanoma among Medicare beneficiaries
BACKGROUND Since 2011, the therapeutic landscape of melanoma has changed
dramatically because of the adoption of immune checkpoint inhibitor and targeted therapies …
dramatically because of the adoption of immune checkpoint inhibitor and targeted therapies …
Estimates of Medicaid and non-medicaid net prices of top-selling brand-name drugs incorporating best price rebates, 2015 to 2019
L Clemans-Cope, M Epstein, J Banthin… - JAMA Health …, 2023 - jamanetwork.com
Importance The US spends far more on brand-name prescription drugs than other
comparable countries. However, studies of prescription drug spending in the US are often …
comparable countries. However, studies of prescription drug spending in the US are often …
Decomposition analysis of spending and price trends for biologic antirheumatic drugs in Medicare and Medicaid
N McCormick, ZS Wallace, CA Sacks… - Arthritis & …, 2020 - Wiley Online Library
Objective Billions of public dollars are spent each year on biologic disease‐modifying
antirheumatic drugs (DMARD s), but the drivers of recent increases in biologic DMARD …
antirheumatic drugs (DMARD s), but the drivers of recent increases in biologic DMARD …
[HTML][HTML] Payment incentives and the use of higher-cost drugs: a retrospective cohort analysis of intravenous iron in the medicare population
BC Hambley, KE Anderson, SP Shanbhag… - The American journal …, 2020 - ncbi.nlm.nih.gov
OBJECTIVES: Medicare Part B payment methods incentivize the use of more expensive
injectable and infused drugs. We examined prescribing patterns in the context of …
injectable and infused drugs. We examined prescribing patterns in the context of …
Profiting from Most-Favored-Customer Procurement Rules: Evidence from Medicaid
Using a difference-in-difference approach, we find that an increase to Medicaid's minimum
drug rebate under the Affordable Care Act in 2010 lowered non-Medicaid drug spending by …
drug rebate under the Affordable Care Act in 2010 lowered non-Medicaid drug spending by …